mouse monoclonal anti-brafv600e antibody, clone ve1 Search Results


90
Spring Bioscience anti-human brafv600e
BRAF transcript variants in the context of acquired resistance to BRAF and MEK inhibitors. a Real-time PCR detection of total BRAF ( red ), BRAF -ref ( grey ), BRAF -X1 plus X2 ( black ), BRAF -X1 ( blue ), and BRAF -X2 ( green ) in 451Lu parental cells (P) and in 451Lu-MR resistant cells (MR). The latter show acquired resistance to BRAF and MEK inhibitors due to the focal amplification of the BRAF gene. b Cartoon summarizing the position of the primers and the siRNAs used to determine the presence and the level of the Δ[3–10] variant of BRAF . For details, please refer to Additional file : Figure S17. c Real-time PCR detection of total BRAF ( red ), full length BRAF ( brown ), Δ[3–10] BRAF ( orange , left panel ), BRAF -ref ( grey ), BRAF -X1 plus X2 ( black ), BRAF -X1 ( blue ), and BRAF -X2 ( green , right panel ) in A375 parental cells and in A375 C2 cells. The latter show acquired resistance to vemurafenib due to the presence of <t>Δ[3–10]BRAFV600E</t> splicing variant. d PCR amplification of the reference, X1, and X2 Δ[3–10] BRAF splicing variants from the cDNA of A375 C2 cells. Lane 1: 1 kbp ladder. Lane 2: Δ[3–10] BRAF -ref amplification was obtained using BRAF -E1/2 F primer and ref BRAF -STOP R primer (open red and grey arrows in b ). Lane 3: Δ[3–10] BRAF -ref CDS was amplified from pMSCVHygro-Δ[3–10]BRAFV600E-ref plasmid and used as positive control. Lane 4: the amplification of Δ[3–10] BRAF -X1 ( upper band ) and Δ[3–10] BRAF -X2 ( lower band ) was obtained using BRAF -E1/2 F primer and BRAF -X1-STOP R primer (open red and black arrows in b ). Lane 5: Δ[3–10] BRAF -X1 CDS was amplified from pMSCVHygro-Δ[3–10]BRAFV600E-X1 plasmid and used as positive control. Lane 6: Δ[3–10] BRAF -X2 CDS was amplified from pMSCVHygro-Δ[3–10]BRAFV600E-X2 plasmid and used as positive control. e - f Real-time PCR detection of full length BRAF , Δ[3–10] BRAF , BRAF -ref , BRAF- X1 plus X2, BRAF -X1, and BRAF -X2 24 h after the transfection of si-fl BRAF ( e ) and si-Δ[3–10] BRAF ( f ) in A375 C2 cells. g Real-time PCR detection of full length and Δ[3–10] BRAF 24 h after the transfection of si-ref BRAF and si- BRAF -E19-1 in A375 C2 cells. h Western blot of full length and Δ[3–10] BRAFV600E, as well as of pMEK 48 h after the transfection of the indicated siRNAs or siRNA mixes in A375 C2 cells. i Growth curve of A375 C2 cells after the transfection of the indicated siRNAs. Throughout the experiment, the cells were kept in DMSO ( left panel ) or in 2 uM vemurafenib ( right panel ). The arrows highlight the increased sensitivity displayed by A375 C2 cells to si-Δ[3–10] BRAF ( orange ) and si- BRAF -E19-1 ( black ), when grown in vemurafenib. The graph represents the mean only of 3 independent experiments. ( j ) Colony formation assay of A375 C2 cells after the transfection of the indicated siRNAs. Throughout the experiment, the cells were kept in DMSO ( clean bars ) or in 2 uM vemurafenib ( dashed bars ). The pictures are taken from 1 out of 3 independent experiments performed, all with comparable outcome. The graphs represent the mean ± SEM (or mean ± SD in a and c ) of 3 independent experiments. * p < 0.05, ** p < 0.01
Anti Human Brafv600e, supplied by Spring Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+monoclonal+anti-brafv600e+antibody%2C+clone+ve1/braf+v600e+antibody/pmc05410044-356-29-33
Average 90 stars, based on 1 article reviews
anti-human brafv600e - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
NewEast Biosciences brafv600e antibody
BRAF transcript variants in the context of acquired resistance to BRAF and MEK inhibitors. a Real-time PCR detection of total BRAF ( red ), BRAF -ref ( grey ), BRAF -X1 plus X2 ( black ), BRAF -X1 ( blue ), and BRAF -X2 ( green ) in 451Lu parental cells (P) and in 451Lu-MR resistant cells (MR). The latter show acquired resistance to BRAF and MEK inhibitors due to the focal amplification of the BRAF gene. b Cartoon summarizing the position of the primers and the siRNAs used to determine the presence and the level of the Δ[3–10] variant of BRAF . For details, please refer to Additional file : Figure S17. c Real-time PCR detection of total BRAF ( red ), full length BRAF ( brown ), Δ[3–10] BRAF ( orange , left panel ), BRAF -ref ( grey ), BRAF -X1 plus X2 ( black ), BRAF -X1 ( blue ), and BRAF -X2 ( green , right panel ) in A375 parental cells and in A375 C2 cells. The latter show acquired resistance to vemurafenib due to the presence of <t>Δ[3–10]BRAFV600E</t> splicing variant. d PCR amplification of the reference, X1, and X2 Δ[3–10] BRAF splicing variants from the cDNA of A375 C2 cells. Lane 1: 1 kbp ladder. Lane 2: Δ[3–10] BRAF -ref amplification was obtained using BRAF -E1/2 F primer and ref BRAF -STOP R primer (open red and grey arrows in b ). Lane 3: Δ[3–10] BRAF -ref CDS was amplified from pMSCVHygro-Δ[3–10]BRAFV600E-ref plasmid and used as positive control. Lane 4: the amplification of Δ[3–10] BRAF -X1 ( upper band ) and Δ[3–10] BRAF -X2 ( lower band ) was obtained using BRAF -E1/2 F primer and BRAF -X1-STOP R primer (open red and black arrows in b ). Lane 5: Δ[3–10] BRAF -X1 CDS was amplified from pMSCVHygro-Δ[3–10]BRAFV600E-X1 plasmid and used as positive control. Lane 6: Δ[3–10] BRAF -X2 CDS was amplified from pMSCVHygro-Δ[3–10]BRAFV600E-X2 plasmid and used as positive control. e - f Real-time PCR detection of full length BRAF , Δ[3–10] BRAF , BRAF -ref , BRAF- X1 plus X2, BRAF -X1, and BRAF -X2 24 h after the transfection of si-fl BRAF ( e ) and si-Δ[3–10] BRAF ( f ) in A375 C2 cells. g Real-time PCR detection of full length and Δ[3–10] BRAF 24 h after the transfection of si-ref BRAF and si- BRAF -E19-1 in A375 C2 cells. h Western blot of full length and Δ[3–10] BRAFV600E, as well as of pMEK 48 h after the transfection of the indicated siRNAs or siRNA mixes in A375 C2 cells. i Growth curve of A375 C2 cells after the transfection of the indicated siRNAs. Throughout the experiment, the cells were kept in DMSO ( left panel ) or in 2 uM vemurafenib ( right panel ). The arrows highlight the increased sensitivity displayed by A375 C2 cells to si-Δ[3–10] BRAF ( orange ) and si- BRAF -E19-1 ( black ), when grown in vemurafenib. The graph represents the mean only of 3 independent experiments. ( j ) Colony formation assay of A375 C2 cells after the transfection of the indicated siRNAs. Throughout the experiment, the cells were kept in DMSO ( clean bars ) or in 2 uM vemurafenib ( dashed bars ). The pictures are taken from 1 out of 3 independent experiments performed, all with comparable outcome. The graphs represent the mean ± SEM (or mean ± SD in a and c ) of 3 independent experiments. * p < 0.05, ** p < 0.01
Brafv600e Antibody, supplied by NewEast Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+monoclonal+anti-brafv600e+antibody%2C+clone+ve1/mouse+anti+braf+v600e+antibody/us10941452-345-18-22
Average 90 stars, based on 1 article reviews
brafv600e antibody - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
RevMAb Inc rabbit anti-brafv600e (rm8)
BRAF transcript variants in the context of acquired resistance to BRAF and MEK inhibitors. a Real-time PCR detection of total BRAF ( red ), BRAF -ref ( grey ), BRAF -X1 plus X2 ( black ), BRAF -X1 ( blue ), and BRAF -X2 ( green ) in 451Lu parental cells (P) and in 451Lu-MR resistant cells (MR). The latter show acquired resistance to BRAF and MEK inhibitors due to the focal amplification of the BRAF gene. b Cartoon summarizing the position of the primers and the siRNAs used to determine the presence and the level of the Δ[3–10] variant of BRAF . For details, please refer to Additional file : Figure S17. c Real-time PCR detection of total BRAF ( red ), full length BRAF ( brown ), Δ[3–10] BRAF ( orange , left panel ), BRAF -ref ( grey ), BRAF -X1 plus X2 ( black ), BRAF -X1 ( blue ), and BRAF -X2 ( green , right panel ) in A375 parental cells and in A375 C2 cells. The latter show acquired resistance to vemurafenib due to the presence of <t>Δ[3–10]BRAFV600E</t> splicing variant. d PCR amplification of the reference, X1, and X2 Δ[3–10] BRAF splicing variants from the cDNA of A375 C2 cells. Lane 1: 1 kbp ladder. Lane 2: Δ[3–10] BRAF -ref amplification was obtained using BRAF -E1/2 F primer and ref BRAF -STOP R primer (open red and grey arrows in b ). Lane 3: Δ[3–10] BRAF -ref CDS was amplified from pMSCVHygro-Δ[3–10]BRAFV600E-ref plasmid and used as positive control. Lane 4: the amplification of Δ[3–10] BRAF -X1 ( upper band ) and Δ[3–10] BRAF -X2 ( lower band ) was obtained using BRAF -E1/2 F primer and BRAF -X1-STOP R primer (open red and black arrows in b ). Lane 5: Δ[3–10] BRAF -X1 CDS was amplified from pMSCVHygro-Δ[3–10]BRAFV600E-X1 plasmid and used as positive control. Lane 6: Δ[3–10] BRAF -X2 CDS was amplified from pMSCVHygro-Δ[3–10]BRAFV600E-X2 plasmid and used as positive control. e - f Real-time PCR detection of full length BRAF , Δ[3–10] BRAF , BRAF -ref , BRAF- X1 plus X2, BRAF -X1, and BRAF -X2 24 h after the transfection of si-fl BRAF ( e ) and si-Δ[3–10] BRAF ( f ) in A375 C2 cells. g Real-time PCR detection of full length and Δ[3–10] BRAF 24 h after the transfection of si-ref BRAF and si- BRAF -E19-1 in A375 C2 cells. h Western blot of full length and Δ[3–10] BRAFV600E, as well as of pMEK 48 h after the transfection of the indicated siRNAs or siRNA mixes in A375 C2 cells. i Growth curve of A375 C2 cells after the transfection of the indicated siRNAs. Throughout the experiment, the cells were kept in DMSO ( left panel ) or in 2 uM vemurafenib ( right panel ). The arrows highlight the increased sensitivity displayed by A375 C2 cells to si-Δ[3–10] BRAF ( orange ) and si- BRAF -E19-1 ( black ), when grown in vemurafenib. The graph represents the mean only of 3 independent experiments. ( j ) Colony formation assay of A375 C2 cells after the transfection of the indicated siRNAs. Throughout the experiment, the cells were kept in DMSO ( clean bars ) or in 2 uM vemurafenib ( dashed bars ). The pictures are taken from 1 out of 3 independent experiments performed, all with comparable outcome. The graphs represent the mean ± SEM (or mean ± SD in a and c ) of 3 independent experiments. * p < 0.05, ** p < 0.01
Rabbit Anti Brafv600e (Rm8), supplied by RevMAb Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+monoclonal+anti-brafv600e+antibody%2C+clone+ve1/braf+v600e++rm8++antibody/pmc09674643-40-0-5
Average 90 stars, based on 1 article reviews
rabbit anti-brafv600e (rm8) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

99
Danaher Inc mouse monoclonal antibody
BRAF transcript variants in the context of acquired resistance to BRAF and MEK inhibitors. a Real-time PCR detection of total BRAF ( red ), BRAF -ref ( grey ), BRAF -X1 plus X2 ( black ), BRAF -X1 ( blue ), and BRAF -X2 ( green ) in 451Lu parental cells (P) and in 451Lu-MR resistant cells (MR). The latter show acquired resistance to BRAF and MEK inhibitors due to the focal amplification of the BRAF gene. b Cartoon summarizing the position of the primers and the siRNAs used to determine the presence and the level of the Δ[3–10] variant of BRAF . For details, please refer to Additional file : Figure S17. c Real-time PCR detection of total BRAF ( red ), full length BRAF ( brown ), Δ[3–10] BRAF ( orange , left panel ), BRAF -ref ( grey ), BRAF -X1 plus X2 ( black ), BRAF -X1 ( blue ), and BRAF -X2 ( green , right panel ) in A375 parental cells and in A375 C2 cells. The latter show acquired resistance to vemurafenib due to the presence of <t>Δ[3–10]BRAFV600E</t> splicing variant. d PCR amplification of the reference, X1, and X2 Δ[3–10] BRAF splicing variants from the cDNA of A375 C2 cells. Lane 1: 1 kbp ladder. Lane 2: Δ[3–10] BRAF -ref amplification was obtained using BRAF -E1/2 F primer and ref BRAF -STOP R primer (open red and grey arrows in b ). Lane 3: Δ[3–10] BRAF -ref CDS was amplified from pMSCVHygro-Δ[3–10]BRAFV600E-ref plasmid and used as positive control. Lane 4: the amplification of Δ[3–10] BRAF -X1 ( upper band ) and Δ[3–10] BRAF -X2 ( lower band ) was obtained using BRAF -E1/2 F primer and BRAF -X1-STOP R primer (open red and black arrows in b ). Lane 5: Δ[3–10] BRAF -X1 CDS was amplified from pMSCVHygro-Δ[3–10]BRAFV600E-X1 plasmid and used as positive control. Lane 6: Δ[3–10] BRAF -X2 CDS was amplified from pMSCVHygro-Δ[3–10]BRAFV600E-X2 plasmid and used as positive control. e - f Real-time PCR detection of full length BRAF , Δ[3–10] BRAF , BRAF -ref , BRAF- X1 plus X2, BRAF -X1, and BRAF -X2 24 h after the transfection of si-fl BRAF ( e ) and si-Δ[3–10] BRAF ( f ) in A375 C2 cells. g Real-time PCR detection of full length and Δ[3–10] BRAF 24 h after the transfection of si-ref BRAF and si- BRAF -E19-1 in A375 C2 cells. h Western blot of full length and Δ[3–10] BRAFV600E, as well as of pMEK 48 h after the transfection of the indicated siRNAs or siRNA mixes in A375 C2 cells. i Growth curve of A375 C2 cells after the transfection of the indicated siRNAs. Throughout the experiment, the cells were kept in DMSO ( left panel ) or in 2 uM vemurafenib ( right panel ). The arrows highlight the increased sensitivity displayed by A375 C2 cells to si-Δ[3–10] BRAF ( orange ) and si- BRAF -E19-1 ( black ), when grown in vemurafenib. The graph represents the mean only of 3 independent experiments. ( j ) Colony formation assay of A375 C2 cells after the transfection of the indicated siRNAs. Throughout the experiment, the cells were kept in DMSO ( clean bars ) or in 2 uM vemurafenib ( dashed bars ). The pictures are taken from 1 out of 3 independent experiments performed, all with comparable outcome. The graphs represent the mean ± SEM (or mean ± SD in a and c ) of 3 independent experiments. * p < 0.05, ** p < 0.01
Mouse Monoclonal Antibody, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+monoclonal+anti-brafv600e+antibody%2C+clone+ve1/mouse+monoclonal+Anti-SOX2+antibody/pmc09162746-39-11-14
Average 99 stars, based on 1 article reviews
mouse monoclonal antibody - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

90
Spring Bioscience pan-braf antibody pbr1 clone
BRAF transcript variants in the context of acquired resistance to BRAF and MEK inhibitors. a Real-time PCR detection of total BRAF ( red ), BRAF -ref ( grey ), BRAF -X1 plus X2 ( black ), BRAF -X1 ( blue ), and BRAF -X2 ( green ) in 451Lu parental cells (P) and in 451Lu-MR resistant cells (MR). The latter show acquired resistance to BRAF and MEK inhibitors due to the focal amplification of the BRAF gene. b Cartoon summarizing the position of the primers and the siRNAs used to determine the presence and the level of the Δ[3–10] variant of BRAF . For details, please refer to Additional file : Figure S17. c Real-time PCR detection of total BRAF ( red ), full length BRAF ( brown ), Δ[3–10] BRAF ( orange , left panel ), BRAF -ref ( grey ), BRAF -X1 plus X2 ( black ), BRAF -X1 ( blue ), and BRAF -X2 ( green , right panel ) in A375 parental cells and in A375 C2 cells. The latter show acquired resistance to vemurafenib due to the presence of <t>Δ[3–10]BRAFV600E</t> splicing variant. d PCR amplification of the reference, X1, and X2 Δ[3–10] BRAF splicing variants from the cDNA of A375 C2 cells. Lane 1: 1 kbp ladder. Lane 2: Δ[3–10] BRAF -ref amplification was obtained using BRAF -E1/2 F primer and ref BRAF -STOP R primer (open red and grey arrows in b ). Lane 3: Δ[3–10] BRAF -ref CDS was amplified from pMSCVHygro-Δ[3–10]BRAFV600E-ref plasmid and used as positive control. Lane 4: the amplification of Δ[3–10] BRAF -X1 ( upper band ) and Δ[3–10] BRAF -X2 ( lower band ) was obtained using BRAF -E1/2 F primer and BRAF -X1-STOP R primer (open red and black arrows in b ). Lane 5: Δ[3–10] BRAF -X1 CDS was amplified from pMSCVHygro-Δ[3–10]BRAFV600E-X1 plasmid and used as positive control. Lane 6: Δ[3–10] BRAF -X2 CDS was amplified from pMSCVHygro-Δ[3–10]BRAFV600E-X2 plasmid and used as positive control. e - f Real-time PCR detection of full length BRAF , Δ[3–10] BRAF , BRAF -ref , BRAF- X1 plus X2, BRAF -X1, and BRAF -X2 24 h after the transfection of si-fl BRAF ( e ) and si-Δ[3–10] BRAF ( f ) in A375 C2 cells. g Real-time PCR detection of full length and Δ[3–10] BRAF 24 h after the transfection of si-ref BRAF and si- BRAF -E19-1 in A375 C2 cells. h Western blot of full length and Δ[3–10] BRAFV600E, as well as of pMEK 48 h after the transfection of the indicated siRNAs or siRNA mixes in A375 C2 cells. i Growth curve of A375 C2 cells after the transfection of the indicated siRNAs. Throughout the experiment, the cells were kept in DMSO ( left panel ) or in 2 uM vemurafenib ( right panel ). The arrows highlight the increased sensitivity displayed by A375 C2 cells to si-Δ[3–10] BRAF ( orange ) and si- BRAF -E19-1 ( black ), when grown in vemurafenib. The graph represents the mean only of 3 independent experiments. ( j ) Colony formation assay of A375 C2 cells after the transfection of the indicated siRNAs. Throughout the experiment, the cells were kept in DMSO ( clean bars ) or in 2 uM vemurafenib ( dashed bars ). The pictures are taken from 1 out of 3 independent experiments performed, all with comparable outcome. The graphs represent the mean ± SEM (or mean ± SD in a and c ) of 3 independent experiments. * p < 0.05, ** p < 0.01
Pan Braf Antibody Pbr1 Clone, supplied by Spring Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+monoclonal+anti-brafv600e+antibody%2C+clone+ve1/pan+braf+antibody+pbr1+clone/pmc04912894-48-7-11
Average 90 stars, based on 1 article reviews
pan-braf antibody pbr1 clone - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Cell Marque mouse anti-pdpn
BRAF transcript variants in the context of acquired resistance to BRAF and MEK inhibitors. a Real-time PCR detection of total BRAF ( red ), BRAF -ref ( grey ), BRAF -X1 plus X2 ( black ), BRAF -X1 ( blue ), and BRAF -X2 ( green ) in 451Lu parental cells (P) and in 451Lu-MR resistant cells (MR). The latter show acquired resistance to BRAF and MEK inhibitors due to the focal amplification of the BRAF gene. b Cartoon summarizing the position of the primers and the siRNAs used to determine the presence and the level of the Δ[3–10] variant of BRAF . For details, please refer to Additional file : Figure S17. c Real-time PCR detection of total BRAF ( red ), full length BRAF ( brown ), Δ[3–10] BRAF ( orange , left panel ), BRAF -ref ( grey ), BRAF -X1 plus X2 ( black ), BRAF -X1 ( blue ), and BRAF -X2 ( green , right panel ) in A375 parental cells and in A375 C2 cells. The latter show acquired resistance to vemurafenib due to the presence of <t>Δ[3–10]BRAFV600E</t> splicing variant. d PCR amplification of the reference, X1, and X2 Δ[3–10] BRAF splicing variants from the cDNA of A375 C2 cells. Lane 1: 1 kbp ladder. Lane 2: Δ[3–10] BRAF -ref amplification was obtained using BRAF -E1/2 F primer and ref BRAF -STOP R primer (open red and grey arrows in b ). Lane 3: Δ[3–10] BRAF -ref CDS was amplified from pMSCVHygro-Δ[3–10]BRAFV600E-ref plasmid and used as positive control. Lane 4: the amplification of Δ[3–10] BRAF -X1 ( upper band ) and Δ[3–10] BRAF -X2 ( lower band ) was obtained using BRAF -E1/2 F primer and BRAF -X1-STOP R primer (open red and black arrows in b ). Lane 5: Δ[3–10] BRAF -X1 CDS was amplified from pMSCVHygro-Δ[3–10]BRAFV600E-X1 plasmid and used as positive control. Lane 6: Δ[3–10] BRAF -X2 CDS was amplified from pMSCVHygro-Δ[3–10]BRAFV600E-X2 plasmid and used as positive control. e - f Real-time PCR detection of full length BRAF , Δ[3–10] BRAF , BRAF -ref , BRAF- X1 plus X2, BRAF -X1, and BRAF -X2 24 h after the transfection of si-fl BRAF ( e ) and si-Δ[3–10] BRAF ( f ) in A375 C2 cells. g Real-time PCR detection of full length and Δ[3–10] BRAF 24 h after the transfection of si-ref BRAF and si- BRAF -E19-1 in A375 C2 cells. h Western blot of full length and Δ[3–10] BRAFV600E, as well as of pMEK 48 h after the transfection of the indicated siRNAs or siRNA mixes in A375 C2 cells. i Growth curve of A375 C2 cells after the transfection of the indicated siRNAs. Throughout the experiment, the cells were kept in DMSO ( left panel ) or in 2 uM vemurafenib ( right panel ). The arrows highlight the increased sensitivity displayed by A375 C2 cells to si-Δ[3–10] BRAF ( orange ) and si- BRAF -E19-1 ( black ), when grown in vemurafenib. The graph represents the mean only of 3 independent experiments. ( j ) Colony formation assay of A375 C2 cells after the transfection of the indicated siRNAs. Throughout the experiment, the cells were kept in DMSO ( clean bars ) or in 2 uM vemurafenib ( dashed bars ). The pictures are taken from 1 out of 3 independent experiments performed, all with comparable outcome. The graphs represent the mean ± SEM (or mean ± SD in a and c ) of 3 independent experiments. * p < 0.05, ** p < 0.01
Mouse Anti Pdpn, supplied by Cell Marque, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+monoclonal+anti-brafv600e+antibody%2C+clone+ve1/mouse+anti+pdpn/pmc08972000__mmc1-27-26-32
Average 90 stars, based on 1 article reviews
mouse anti-pdpn - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Spring Bioscience ve1 mouse monoclonal antibody
BRAF transcript variants in the context of acquired resistance to BRAF and MEK inhibitors. a Real-time PCR detection of total BRAF ( red ), BRAF -ref ( grey ), BRAF -X1 plus X2 ( black ), BRAF -X1 ( blue ), and BRAF -X2 ( green ) in 451Lu parental cells (P) and in 451Lu-MR resistant cells (MR). The latter show acquired resistance to BRAF and MEK inhibitors due to the focal amplification of the BRAF gene. b Cartoon summarizing the position of the primers and the siRNAs used to determine the presence and the level of the Δ[3–10] variant of BRAF . For details, please refer to Additional file : Figure S17. c Real-time PCR detection of total BRAF ( red ), full length BRAF ( brown ), Δ[3–10] BRAF ( orange , left panel ), BRAF -ref ( grey ), BRAF -X1 plus X2 ( black ), BRAF -X1 ( blue ), and BRAF -X2 ( green , right panel ) in A375 parental cells and in A375 C2 cells. The latter show acquired resistance to vemurafenib due to the presence of <t>Δ[3–10]BRAFV600E</t> splicing variant. d PCR amplification of the reference, X1, and X2 Δ[3–10] BRAF splicing variants from the cDNA of A375 C2 cells. Lane 1: 1 kbp ladder. Lane 2: Δ[3–10] BRAF -ref amplification was obtained using BRAF -E1/2 F primer and ref BRAF -STOP R primer (open red and grey arrows in b ). Lane 3: Δ[3–10] BRAF -ref CDS was amplified from pMSCVHygro-Δ[3–10]BRAFV600E-ref plasmid and used as positive control. Lane 4: the amplification of Δ[3–10] BRAF -X1 ( upper band ) and Δ[3–10] BRAF -X2 ( lower band ) was obtained using BRAF -E1/2 F primer and BRAF -X1-STOP R primer (open red and black arrows in b ). Lane 5: Δ[3–10] BRAF -X1 CDS was amplified from pMSCVHygro-Δ[3–10]BRAFV600E-X1 plasmid and used as positive control. Lane 6: Δ[3–10] BRAF -X2 CDS was amplified from pMSCVHygro-Δ[3–10]BRAFV600E-X2 plasmid and used as positive control. e - f Real-time PCR detection of full length BRAF , Δ[3–10] BRAF , BRAF -ref , BRAF- X1 plus X2, BRAF -X1, and BRAF -X2 24 h after the transfection of si-fl BRAF ( e ) and si-Δ[3–10] BRAF ( f ) in A375 C2 cells. g Real-time PCR detection of full length and Δ[3–10] BRAF 24 h after the transfection of si-ref BRAF and si- BRAF -E19-1 in A375 C2 cells. h Western blot of full length and Δ[3–10] BRAFV600E, as well as of pMEK 48 h after the transfection of the indicated siRNAs or siRNA mixes in A375 C2 cells. i Growth curve of A375 C2 cells after the transfection of the indicated siRNAs. Throughout the experiment, the cells were kept in DMSO ( left panel ) or in 2 uM vemurafenib ( right panel ). The arrows highlight the increased sensitivity displayed by A375 C2 cells to si-Δ[3–10] BRAF ( orange ) and si- BRAF -E19-1 ( black ), when grown in vemurafenib. The graph represents the mean only of 3 independent experiments. ( j ) Colony formation assay of A375 C2 cells after the transfection of the indicated siRNAs. Throughout the experiment, the cells were kept in DMSO ( clean bars ) or in 2 uM vemurafenib ( dashed bars ). The pictures are taken from 1 out of 3 independent experiments performed, all with comparable outcome. The graphs represent the mean ± SEM (or mean ± SD in a and c ) of 3 independent experiments. * p < 0.05, ** p < 0.01
Ve1 Mouse Monoclonal Antibody, supplied by Spring Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+monoclonal+anti-brafv600e+antibody%2C+clone+ve1/monoclonal+mouse+antibody+ve1/pm26695089-40-14-18
Average 90 stars, based on 1 article reviews
ve1 mouse monoclonal antibody - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Abnova monoclonal mouse anti-foxm1 antibody clone 3a9
PANC1 cells were used as a positive control. (a) The results of the quantitative RT-PCR analyses of <t>FOXM1</t> mRNA expression. The relative transcript levels of FOXM1 normalized to the level in PANC1 are shown. (b) The expression of FOXM1 proteins in the malignant melanoma cell lines and NHEM. (c) The results of the quantitative RT-PCR analyses of the miR-370 mRNA expression. (d) The results of the semiquantitative RT-PCR using primers that can detect three splicing variants: FOXM1a (472bp), FOXM1b (323bp) and FOXM1c (368bp).
Monoclonal Mouse Anti Foxm1 Antibody Clone 3a9, supplied by Abnova, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+monoclonal+anti-brafv600e+antibody%2C+clone+ve1/anti+foxm1/pmc04671728-102-12-18
Average 90 stars, based on 1 article reviews
monoclonal mouse anti-foxm1 antibody clone 3a9 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

99
Cell Signaling Technology Inc anti phosphoerk1 2
PANC1 cells were used as a positive control. (a) The results of the quantitative RT-PCR analyses of <t>FOXM1</t> mRNA expression. The relative transcript levels of FOXM1 normalized to the level in PANC1 are shown. (b) The expression of FOXM1 proteins in the malignant melanoma cell lines and NHEM. (c) The results of the quantitative RT-PCR analyses of the miR-370 mRNA expression. (d) The results of the semiquantitative RT-PCR using primers that can detect three splicing variants: FOXM1a (472bp), FOXM1b (323bp) and FOXM1c (368bp).
Anti Phosphoerk1 2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+monoclonal+anti-brafv600e+antibody%2C+clone+ve1/beta-Actin+Rabbit+mAb/10__7554_slash_elife__70385-542-25-27
Average 99 stars, based on 1 article reviews
anti phosphoerk1 2 - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc anti hsp90

Anti Hsp90, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+monoclonal+anti-brafv600e+antibody%2C+clone+ve1/HSP90+Antibody/pmc08610417-300-13-14
Average 96 stars, based on 1 article reviews
anti hsp90 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc monoclonal rabbit anti phospho akt ser473 antibody

Monoclonal Rabbit Anti Phospho Akt Ser473 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+monoclonal+anti-brafv600e+antibody%2C+clone+ve1/Phospho-Akt+(Ser473)+Rabbit+mAb/pmc04671728-102-32-37
Average 96 stars, based on 1 article reviews
monoclonal rabbit anti phospho akt ser473 antibody - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

99
Cell Signaling Technology Inc anti pakt

Anti Pakt, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+monoclonal+anti-brafv600e+antibody%2C+clone+ve1/Phospho-Akt+(Ser473)+Antibody/pm39794352-352-44-47
Average 99 stars, based on 1 article reviews
anti pakt - by Bioz Stars, 2026-11
99/100 stars
  Buy from Supplier

Image Search Results


BRAF transcript variants in the context of acquired resistance to BRAF and MEK inhibitors. a Real-time PCR detection of total BRAF ( red ), BRAF -ref ( grey ), BRAF -X1 plus X2 ( black ), BRAF -X1 ( blue ), and BRAF -X2 ( green ) in 451Lu parental cells (P) and in 451Lu-MR resistant cells (MR). The latter show acquired resistance to BRAF and MEK inhibitors due to the focal amplification of the BRAF gene. b Cartoon summarizing the position of the primers and the siRNAs used to determine the presence and the level of the Δ[3–10] variant of BRAF . For details, please refer to Additional file : Figure S17. c Real-time PCR detection of total BRAF ( red ), full length BRAF ( brown ), Δ[3–10] BRAF ( orange , left panel ), BRAF -ref ( grey ), BRAF -X1 plus X2 ( black ), BRAF -X1 ( blue ), and BRAF -X2 ( green , right panel ) in A375 parental cells and in A375 C2 cells. The latter show acquired resistance to vemurafenib due to the presence of Δ[3–10]BRAFV600E splicing variant. d PCR amplification of the reference, X1, and X2 Δ[3–10] BRAF splicing variants from the cDNA of A375 C2 cells. Lane 1: 1 kbp ladder. Lane 2: Δ[3–10] BRAF -ref amplification was obtained using BRAF -E1/2 F primer and ref BRAF -STOP R primer (open red and grey arrows in b ). Lane 3: Δ[3–10] BRAF -ref CDS was amplified from pMSCVHygro-Δ[3–10]BRAFV600E-ref plasmid and used as positive control. Lane 4: the amplification of Δ[3–10] BRAF -X1 ( upper band ) and Δ[3–10] BRAF -X2 ( lower band ) was obtained using BRAF -E1/2 F primer and BRAF -X1-STOP R primer (open red and black arrows in b ). Lane 5: Δ[3–10] BRAF -X1 CDS was amplified from pMSCVHygro-Δ[3–10]BRAFV600E-X1 plasmid and used as positive control. Lane 6: Δ[3–10] BRAF -X2 CDS was amplified from pMSCVHygro-Δ[3–10]BRAFV600E-X2 plasmid and used as positive control. e - f Real-time PCR detection of full length BRAF , Δ[3–10] BRAF , BRAF -ref , BRAF- X1 plus X2, BRAF -X1, and BRAF -X2 24 h after the transfection of si-fl BRAF ( e ) and si-Δ[3–10] BRAF ( f ) in A375 C2 cells. g Real-time PCR detection of full length and Δ[3–10] BRAF 24 h after the transfection of si-ref BRAF and si- BRAF -E19-1 in A375 C2 cells. h Western blot of full length and Δ[3–10] BRAFV600E, as well as of pMEK 48 h after the transfection of the indicated siRNAs or siRNA mixes in A375 C2 cells. i Growth curve of A375 C2 cells after the transfection of the indicated siRNAs. Throughout the experiment, the cells were kept in DMSO ( left panel ) or in 2 uM vemurafenib ( right panel ). The arrows highlight the increased sensitivity displayed by A375 C2 cells to si-Δ[3–10] BRAF ( orange ) and si- BRAF -E19-1 ( black ), when grown in vemurafenib. The graph represents the mean only of 3 independent experiments. ( j ) Colony formation assay of A375 C2 cells after the transfection of the indicated siRNAs. Throughout the experiment, the cells were kept in DMSO ( clean bars ) or in 2 uM vemurafenib ( dashed bars ). The pictures are taken from 1 out of 3 independent experiments performed, all with comparable outcome. The graphs represent the mean ± SEM (or mean ± SD in a and c ) of 3 independent experiments. * p < 0.05, ** p < 0.01

Journal: Molecular Cancer

Article Title: The landscape of BRAF transcript and protein variants in human cancer

doi: 10.1186/s12943-017-0645-4

Figure Lengend Snippet: BRAF transcript variants in the context of acquired resistance to BRAF and MEK inhibitors. a Real-time PCR detection of total BRAF ( red ), BRAF -ref ( grey ), BRAF -X1 plus X2 ( black ), BRAF -X1 ( blue ), and BRAF -X2 ( green ) in 451Lu parental cells (P) and in 451Lu-MR resistant cells (MR). The latter show acquired resistance to BRAF and MEK inhibitors due to the focal amplification of the BRAF gene. b Cartoon summarizing the position of the primers and the siRNAs used to determine the presence and the level of the Δ[3–10] variant of BRAF . For details, please refer to Additional file : Figure S17. c Real-time PCR detection of total BRAF ( red ), full length BRAF ( brown ), Δ[3–10] BRAF ( orange , left panel ), BRAF -ref ( grey ), BRAF -X1 plus X2 ( black ), BRAF -X1 ( blue ), and BRAF -X2 ( green , right panel ) in A375 parental cells and in A375 C2 cells. The latter show acquired resistance to vemurafenib due to the presence of Δ[3–10]BRAFV600E splicing variant. d PCR amplification of the reference, X1, and X2 Δ[3–10] BRAF splicing variants from the cDNA of A375 C2 cells. Lane 1: 1 kbp ladder. Lane 2: Δ[3–10] BRAF -ref amplification was obtained using BRAF -E1/2 F primer and ref BRAF -STOP R primer (open red and grey arrows in b ). Lane 3: Δ[3–10] BRAF -ref CDS was amplified from pMSCVHygro-Δ[3–10]BRAFV600E-ref plasmid and used as positive control. Lane 4: the amplification of Δ[3–10] BRAF -X1 ( upper band ) and Δ[3–10] BRAF -X2 ( lower band ) was obtained using BRAF -E1/2 F primer and BRAF -X1-STOP R primer (open red and black arrows in b ). Lane 5: Δ[3–10] BRAF -X1 CDS was amplified from pMSCVHygro-Δ[3–10]BRAFV600E-X1 plasmid and used as positive control. Lane 6: Δ[3–10] BRAF -X2 CDS was amplified from pMSCVHygro-Δ[3–10]BRAFV600E-X2 plasmid and used as positive control. e - f Real-time PCR detection of full length BRAF , Δ[3–10] BRAF , BRAF -ref , BRAF- X1 plus X2, BRAF -X1, and BRAF -X2 24 h after the transfection of si-fl BRAF ( e ) and si-Δ[3–10] BRAF ( f ) in A375 C2 cells. g Real-time PCR detection of full length and Δ[3–10] BRAF 24 h after the transfection of si-ref BRAF and si- BRAF -E19-1 in A375 C2 cells. h Western blot of full length and Δ[3–10] BRAFV600E, as well as of pMEK 48 h after the transfection of the indicated siRNAs or siRNA mixes in A375 C2 cells. i Growth curve of A375 C2 cells after the transfection of the indicated siRNAs. Throughout the experiment, the cells were kept in DMSO ( left panel ) or in 2 uM vemurafenib ( right panel ). The arrows highlight the increased sensitivity displayed by A375 C2 cells to si-Δ[3–10] BRAF ( orange ) and si- BRAF -E19-1 ( black ), when grown in vemurafenib. The graph represents the mean only of 3 independent experiments. ( j ) Colony formation assay of A375 C2 cells after the transfection of the indicated siRNAs. Throughout the experiment, the cells were kept in DMSO ( clean bars ) or in 2 uM vemurafenib ( dashed bars ). The pictures are taken from 1 out of 3 independent experiments performed, all with comparable outcome. The graphs represent the mean ± SEM (or mean ± SD in a and c ) of 3 independent experiments. * p < 0.05, ** p < 0.01

Article Snippet: They were then incubated overnight at 4 °C with the following primary antibodies: anti-BRAF (F-7, #5284, Santa Cruz Biotechnology; mouse monoclonal antibody, dilution 1:1000 in 5% milk in TBST); anti-human BRAFV600E (VE1, #E19290, Spring Bioscience; mouse monoclonal antibody, dilution 1:400 in 1% milk in TBST); anti-pMEK (#9154, Cell Signaling; rabbit monoclonal antibody, dilution 1:1000 in 3% BSA in TBST); anti-α-TUBULIN (#T9026, Sigma-Aldrich; mouse monoclonal antibody, dilution 1:20000 in 5% milk in TBST); anti-EGFP (#A111-22, Molecular Probes, rabbit polyclonal antibody, dilution 1:2000 in 5% milk in TBST).

Techniques: Real-time Polymerase Chain Reaction, Amplification, Variant Assay, Plasmid Preparation, Positive Control, Transfection, Western Blot, Colony Assay

Identification and characterization of BRAF protein isoforms. a Schematic representation of the 3’ terminal region of reference, X1, and X2 BRAF mRNAs, as well as of the corresponding C-terminal regions of reference, X1, and X2 BRAF proteins. b Immunoprecipitation of BRAF protein in A375 cells. Endogenous BRAF was immunoprecipitated using a specific antibody that recognizes the N-terminal domain (IP-BRAF). As negative control, no antibody was used (No Ab). The basal level of BRAF in the cell lysate is shown in Input. c Identification by mass spectrometry of the C-terminal peptides of BRAF-ref and BRAF-X1. Immunoprecipitated BRAF was subjected to LC-MS analysis. The presence of both isoforms is revealed by the detection of isoform-specific peptides (in green ). d Best transitions (BRAF-ref: 352 and 904; BRAF-X1: 1046 and 1117) of the two BRAF protein isoforms by mass spectrometry (MRM based method). e - f Upon the transient transfection of PIG-BRAFV600E-ref, X1, and X2 plasmids in HEK293T cells, western blot indicates that only reference and X1 BRAFV600E are efficiently translated and able to phosphorylate MEK, while X2 is not ( e ). This occurs in spite of the fact that according to real-time PCR for total BRAF levels, all 3 mRNAs are transcribed at similar levels ( f ). g - i Upon the stable infection of pMSCVHygro-Δ[3–10]BRAFV600E-ref, X1, and X2 plasmids in A375 cells, real-time PCR for total BRAF indicates that all 3 mRNAs are transcribed at similar levels ( g ), but western blot indicates that reference and X1 Δ[3–10]BRAFV600E are efficiently translated and able to phosphorylate MEK even in the presence of vemurafenib, while X2 is not ( h ). Consistently, only Δ[3–10]BRAFV600E-ref and -X1 are able to decrease the sensitivity of A375 cells to vemurafenib ( i ). The pictures are taken from 1 out of 3 independent experiments performed, all with comparable outcome. The graphs represent the mean ± SEM of 3 independent experiments

Journal: Molecular Cancer

Article Title: The landscape of BRAF transcript and protein variants in human cancer

doi: 10.1186/s12943-017-0645-4

Figure Lengend Snippet: Identification and characterization of BRAF protein isoforms. a Schematic representation of the 3’ terminal region of reference, X1, and X2 BRAF mRNAs, as well as of the corresponding C-terminal regions of reference, X1, and X2 BRAF proteins. b Immunoprecipitation of BRAF protein in A375 cells. Endogenous BRAF was immunoprecipitated using a specific antibody that recognizes the N-terminal domain (IP-BRAF). As negative control, no antibody was used (No Ab). The basal level of BRAF in the cell lysate is shown in Input. c Identification by mass spectrometry of the C-terminal peptides of BRAF-ref and BRAF-X1. Immunoprecipitated BRAF was subjected to LC-MS analysis. The presence of both isoforms is revealed by the detection of isoform-specific peptides (in green ). d Best transitions (BRAF-ref: 352 and 904; BRAF-X1: 1046 and 1117) of the two BRAF protein isoforms by mass spectrometry (MRM based method). e - f Upon the transient transfection of PIG-BRAFV600E-ref, X1, and X2 plasmids in HEK293T cells, western blot indicates that only reference and X1 BRAFV600E are efficiently translated and able to phosphorylate MEK, while X2 is not ( e ). This occurs in spite of the fact that according to real-time PCR for total BRAF levels, all 3 mRNAs are transcribed at similar levels ( f ). g - i Upon the stable infection of pMSCVHygro-Δ[3–10]BRAFV600E-ref, X1, and X2 plasmids in A375 cells, real-time PCR for total BRAF indicates that all 3 mRNAs are transcribed at similar levels ( g ), but western blot indicates that reference and X1 Δ[3–10]BRAFV600E are efficiently translated and able to phosphorylate MEK even in the presence of vemurafenib, while X2 is not ( h ). Consistently, only Δ[3–10]BRAFV600E-ref and -X1 are able to decrease the sensitivity of A375 cells to vemurafenib ( i ). The pictures are taken from 1 out of 3 independent experiments performed, all with comparable outcome. The graphs represent the mean ± SEM of 3 independent experiments

Article Snippet: They were then incubated overnight at 4 °C with the following primary antibodies: anti-BRAF (F-7, #5284, Santa Cruz Biotechnology; mouse monoclonal antibody, dilution 1:1000 in 5% milk in TBST); anti-human BRAFV600E (VE1, #E19290, Spring Bioscience; mouse monoclonal antibody, dilution 1:400 in 1% milk in TBST); anti-pMEK (#9154, Cell Signaling; rabbit monoclonal antibody, dilution 1:1000 in 3% BSA in TBST); anti-α-TUBULIN (#T9026, Sigma-Aldrich; mouse monoclonal antibody, dilution 1:20000 in 5% milk in TBST); anti-EGFP (#A111-22, Molecular Probes, rabbit polyclonal antibody, dilution 1:2000 in 5% milk in TBST).

Techniques: Immunoprecipitation, Negative Control, Mass Spectrometry, Liquid Chromatography with Mass Spectroscopy, Transfection, Western Blot, Real-time Polymerase Chain Reaction, Infection

The X2 isoform displays a faster decay due to increased proteosomal-mediated degradation. a Schematic representation of the chimerical protein derived from the fusion of EGFP coding sequence with the CR3 domain of BRAFV600E-ref, X1, and X2 within the pEGFP-C1 plasmid. The asterisk indicates the presence of the V600E mutation. b - e Upon the transient transfection of pEGFP-C1 empty (pEGFP-empty), pEGFP-CR3-ref, pEGFP-CR3-X1, and pEGFP-CR3-X2 plasmids in A375 cells, real-time PCR performed with primers for EGFP and for total BRAF indicates that the chimerical mRNAs are all transcribed at similar levels ( b ), but western blot ( c ), flow cytometry ( d ) and confocal microscopy analysis ( e ) indicate that, when fused with CR3-X2, EGFP protein is expressed at lower levels. The dotted box shows a higher exposure of the anti-EGFP antibody. f - h When PIG-BRAFV600E-ΔCterm plasmid, which lacks the nucleotides encoding for the X2-specific C-terminal domain ( f ), is transiently transfected in HEK293T cells, not only BRAF mRNA ( g ), but also BRAF protein is detectable ( h ). e: empty PIG-NotI; X1: PIG-BRAFV600E-X1 (used as positive control); X2: PIG-BRAFV600E-X2; ΔCterm: PIG-BRAFV600E-ΔCterm. i - j Upon the transient transfection of pEGFP-empty, pEGFP-CR3-ref, pEGFP-CR3-X1, and pEGFP-CR3-X2 plasmids, A375 cells were treated with 100 ug/ml cicloheximide (CHX) ( i ) or 20 uM MG132 ( j ) for 8 h. The CHX treatment indicates that the decay rate of CR3-X2 is faster than that of CR3-ref and CR3-X1, while the MG132 treatment suggests that this is due to higher degradation rate through the ubiquitin-proteasome pathway. k The prediction of potential proteasomal cleavage sites using 3 different algorithms retrieves the indicated X2-specific consensus peptide. ( l ) The mutagenesis of Lys739 into a proteasome-insensitive Arg rescues the expression of the X2 isoform of BRAF protein. e: empty PIG-NotI; X1: PIG-BRAFV600E-X1 (used as positive control); X2: PIG-BRAFV600E-X2; X2 K739R : PIG-BRAFV600E-X2 in which Lys(K)739 has been substituted with Arg(R) (AAA to AGA triplet change). m Cartoon that summarizes the main findings of this article (details in the text). The pictures are taken from 1 out of 3 independent experiments performed, all with comparable outcome. The graphs represent the mean ± SEM of 3 independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001

Journal: Molecular Cancer

Article Title: The landscape of BRAF transcript and protein variants in human cancer

doi: 10.1186/s12943-017-0645-4

Figure Lengend Snippet: The X2 isoform displays a faster decay due to increased proteosomal-mediated degradation. a Schematic representation of the chimerical protein derived from the fusion of EGFP coding sequence with the CR3 domain of BRAFV600E-ref, X1, and X2 within the pEGFP-C1 plasmid. The asterisk indicates the presence of the V600E mutation. b - e Upon the transient transfection of pEGFP-C1 empty (pEGFP-empty), pEGFP-CR3-ref, pEGFP-CR3-X1, and pEGFP-CR3-X2 plasmids in A375 cells, real-time PCR performed with primers for EGFP and for total BRAF indicates that the chimerical mRNAs are all transcribed at similar levels ( b ), but western blot ( c ), flow cytometry ( d ) and confocal microscopy analysis ( e ) indicate that, when fused with CR3-X2, EGFP protein is expressed at lower levels. The dotted box shows a higher exposure of the anti-EGFP antibody. f - h When PIG-BRAFV600E-ΔCterm plasmid, which lacks the nucleotides encoding for the X2-specific C-terminal domain ( f ), is transiently transfected in HEK293T cells, not only BRAF mRNA ( g ), but also BRAF protein is detectable ( h ). e: empty PIG-NotI; X1: PIG-BRAFV600E-X1 (used as positive control); X2: PIG-BRAFV600E-X2; ΔCterm: PIG-BRAFV600E-ΔCterm. i - j Upon the transient transfection of pEGFP-empty, pEGFP-CR3-ref, pEGFP-CR3-X1, and pEGFP-CR3-X2 plasmids, A375 cells were treated with 100 ug/ml cicloheximide (CHX) ( i ) or 20 uM MG132 ( j ) for 8 h. The CHX treatment indicates that the decay rate of CR3-X2 is faster than that of CR3-ref and CR3-X1, while the MG132 treatment suggests that this is due to higher degradation rate through the ubiquitin-proteasome pathway. k The prediction of potential proteasomal cleavage sites using 3 different algorithms retrieves the indicated X2-specific consensus peptide. ( l ) The mutagenesis of Lys739 into a proteasome-insensitive Arg rescues the expression of the X2 isoform of BRAF protein. e: empty PIG-NotI; X1: PIG-BRAFV600E-X1 (used as positive control); X2: PIG-BRAFV600E-X2; X2 K739R : PIG-BRAFV600E-X2 in which Lys(K)739 has been substituted with Arg(R) (AAA to AGA triplet change). m Cartoon that summarizes the main findings of this article (details in the text). The pictures are taken from 1 out of 3 independent experiments performed, all with comparable outcome. The graphs represent the mean ± SEM of 3 independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001

Article Snippet: They were then incubated overnight at 4 °C with the following primary antibodies: anti-BRAF (F-7, #5284, Santa Cruz Biotechnology; mouse monoclonal antibody, dilution 1:1000 in 5% milk in TBST); anti-human BRAFV600E (VE1, #E19290, Spring Bioscience; mouse monoclonal antibody, dilution 1:400 in 1% milk in TBST); anti-pMEK (#9154, Cell Signaling; rabbit monoclonal antibody, dilution 1:1000 in 3% BSA in TBST); anti-α-TUBULIN (#T9026, Sigma-Aldrich; mouse monoclonal antibody, dilution 1:20000 in 5% milk in TBST); anti-EGFP (#A111-22, Molecular Probes, rabbit polyclonal antibody, dilution 1:2000 in 5% milk in TBST).

Techniques: Derivative Assay, Sequencing, Plasmid Preparation, Mutagenesis, Transfection, Real-time Polymerase Chain Reaction, Western Blot, Flow Cytometry, Confocal Microscopy, Positive Control, Expressing

PANC1 cells were used as a positive control. (a) The results of the quantitative RT-PCR analyses of FOXM1 mRNA expression. The relative transcript levels of FOXM1 normalized to the level in PANC1 are shown. (b) The expression of FOXM1 proteins in the malignant melanoma cell lines and NHEM. (c) The results of the quantitative RT-PCR analyses of the miR-370 mRNA expression. (d) The results of the semiquantitative RT-PCR using primers that can detect three splicing variants: FOXM1a (472bp), FOXM1b (323bp) and FOXM1c (368bp).

Journal: PLoS ONE

Article Title: Investigation of FOXM1 as a Potential New Target for Melanoma

doi: 10.1371/journal.pone.0144241

Figure Lengend Snippet: PANC1 cells were used as a positive control. (a) The results of the quantitative RT-PCR analyses of FOXM1 mRNA expression. The relative transcript levels of FOXM1 normalized to the level in PANC1 are shown. (b) The expression of FOXM1 proteins in the malignant melanoma cell lines and NHEM. (c) The results of the quantitative RT-PCR analyses of the miR-370 mRNA expression. (d) The results of the semiquantitative RT-PCR using primers that can detect three splicing variants: FOXM1a (472bp), FOXM1b (323bp) and FOXM1c (368bp).

Article Snippet: Sections of paraffin-embedded melanomas and nevus tissue samples were stained with a monoclonal mouse anti-FOXM1 antibody (clone 3A9; Abnova, Taipei, Taiwan), monoclonal mouse anti-BRAFV600E antibody (clone VE1; Spring Bioscience, Pleasanton, CA) and monoclonal rabbit anti-phospho-AKT (Ser473) antibody (Cell Signaling Technologies, Tokyo, Japan).

Techniques: Positive Control, Quantitative RT-PCR, Expressing, Reverse Transcription Polymerase Chain Reaction

The FOXM1 expression (normalized to GAPDH) in the patients with primary melanoma (n = 25), metastatic melanoma (n = 9) and nevi (n = 10) is shown. The bars indicate the median values.

Journal: PLoS ONE

Article Title: Investigation of FOXM1 as a Potential New Target for Melanoma

doi: 10.1371/journal.pone.0144241

Figure Lengend Snippet: The FOXM1 expression (normalized to GAPDH) in the patients with primary melanoma (n = 25), metastatic melanoma (n = 9) and nevi (n = 10) is shown. The bars indicate the median values.

Article Snippet: Sections of paraffin-embedded melanomas and nevus tissue samples were stained with a monoclonal mouse anti-FOXM1 antibody (clone 3A9; Abnova, Taipei, Taiwan), monoclonal mouse anti-BRAFV600E antibody (clone VE1; Spring Bioscience, Pleasanton, CA) and monoclonal rabbit anti-phospho-AKT (Ser473) antibody (Cell Signaling Technologies, Tokyo, Japan).

Techniques: Expressing

Representative images of the immunohistochemical staining for FOXM1 in primary malignant melanoma (a, b, c, d, e) and nevus tissues samples (f, g, h). Hematoxylin and eosin staining (a, f: × 40) and FOXM1 immunohistochemistry (b, g: × 40, c, h: × 400). Negative controls using an isotype monoclonal antibody were presented in d and e (d: × 40, e: × 400). Melanin granules are indicated by blue staining, although they did not exhibit FOXM1 expression. Bars: 500 μm (a, b, d, f, g), 50 μm (c, e, h).

Journal: PLoS ONE

Article Title: Investigation of FOXM1 as a Potential New Target for Melanoma

doi: 10.1371/journal.pone.0144241

Figure Lengend Snippet: Representative images of the immunohistochemical staining for FOXM1 in primary malignant melanoma (a, b, c, d, e) and nevus tissues samples (f, g, h). Hematoxylin and eosin staining (a, f: × 40) and FOXM1 immunohistochemistry (b, g: × 40, c, h: × 400). Negative controls using an isotype monoclonal antibody were presented in d and e (d: × 40, e: × 400). Melanin granules are indicated by blue staining, although they did not exhibit FOXM1 expression. Bars: 500 μm (a, b, d, f, g), 50 μm (c, e, h).

Article Snippet: Sections of paraffin-embedded melanomas and nevus tissue samples were stained with a monoclonal mouse anti-FOXM1 antibody (clone 3A9; Abnova, Taipei, Taiwan), monoclonal mouse anti-BRAFV600E antibody (clone VE1; Spring Bioscience, Pleasanton, CA) and monoclonal rabbit anti-phospho-AKT (Ser473) antibody (Cell Signaling Technologies, Tokyo, Japan).

Techniques: Immunohistochemical staining, Staining, Immunohistochemistry, Expressing

The results of the immunohistochemical analysis of  FOXM1.

Journal: PLoS ONE

Article Title: Investigation of FOXM1 as a Potential New Target for Melanoma

doi: 10.1371/journal.pone.0144241

Figure Lengend Snippet: The results of the immunohistochemical analysis of FOXM1.

Article Snippet: Sections of paraffin-embedded melanomas and nevus tissue samples were stained with a monoclonal mouse anti-FOXM1 antibody (clone 3A9; Abnova, Taipei, Taiwan), monoclonal mouse anti-BRAFV600E antibody (clone VE1; Spring Bioscience, Pleasanton, CA) and monoclonal rabbit anti-phospho-AKT (Ser473) antibody (Cell Signaling Technologies, Tokyo, Japan).

Techniques: Immunohistochemical staining

The results of the immunohistochemical analysis of  FOXM1,  BRAFV600E and p-AKT.

Journal: PLoS ONE

Article Title: Investigation of FOXM1 as a Potential New Target for Melanoma

doi: 10.1371/journal.pone.0144241

Figure Lengend Snippet: The results of the immunohistochemical analysis of FOXM1, BRAFV600E and p-AKT.

Article Snippet: Sections of paraffin-embedded melanomas and nevus tissue samples were stained with a monoclonal mouse anti-FOXM1 antibody (clone 3A9; Abnova, Taipei, Taiwan), monoclonal mouse anti-BRAFV600E antibody (clone VE1; Spring Bioscience, Pleasanton, CA) and monoclonal rabbit anti-phospho-AKT (Ser473) antibody (Cell Signaling Technologies, Tokyo, Japan).

Techniques: Immunohistochemical staining

The correlation between  FOXM1  expression and the tumor thickness.

Journal: PLoS ONE

Article Title: Investigation of FOXM1 as a Potential New Target for Melanoma

doi: 10.1371/journal.pone.0144241

Figure Lengend Snippet: The correlation between FOXM1 expression and the tumor thickness.

Article Snippet: Sections of paraffin-embedded melanomas and nevus tissue samples were stained with a monoclonal mouse anti-FOXM1 antibody (clone 3A9; Abnova, Taipei, Taiwan), monoclonal mouse anti-BRAFV600E antibody (clone VE1; Spring Bioscience, Pleasanton, CA) and monoclonal rabbit anti-phospho-AKT (Ser473) antibody (Cell Signaling Technologies, Tokyo, Japan).

Techniques: Expressing

A comparison of the overall survival between the patients positive for FOXM1 and those negative for expression, as determined using immunohistochemical staining. The p -values were determined using the log-rank test.

Journal: PLoS ONE

Article Title: Investigation of FOXM1 as a Potential New Target for Melanoma

doi: 10.1371/journal.pone.0144241

Figure Lengend Snippet: A comparison of the overall survival between the patients positive for FOXM1 and those negative for expression, as determined using immunohistochemical staining. The p -values were determined using the log-rank test.

Article Snippet: Sections of paraffin-embedded melanomas and nevus tissue samples were stained with a monoclonal mouse anti-FOXM1 antibody (clone 3A9; Abnova, Taipei, Taiwan), monoclonal mouse anti-BRAFV600E antibody (clone VE1; Spring Bioscience, Pleasanton, CA) and monoclonal rabbit anti-phospho-AKT (Ser473) antibody (Cell Signaling Technologies, Tokyo, Japan).

Techniques: Comparison, Expressing, Immunohistochemical staining, Staining

The human melanoma cell lines, MeWo and SK-MEL28, were transfected with control and FOXM1 siRNA. Twenty-four hours after treatment, the quantitative RT-PCR analyses were carried out (a,). Seventy-two hours after treatment, a Western blotting analysis and the BrdU cell proliferation assay were performed (b, c). The p -values were determined using the Mann–Whitney U-test. * p < 0.05.

Journal: PLoS ONE

Article Title: Investigation of FOXM1 as a Potential New Target for Melanoma

doi: 10.1371/journal.pone.0144241

Figure Lengend Snippet: The human melanoma cell lines, MeWo and SK-MEL28, were transfected with control and FOXM1 siRNA. Twenty-four hours after treatment, the quantitative RT-PCR analyses were carried out (a,). Seventy-two hours after treatment, a Western blotting analysis and the BrdU cell proliferation assay were performed (b, c). The p -values were determined using the Mann–Whitney U-test. * p < 0.05.

Article Snippet: Sections of paraffin-embedded melanomas and nevus tissue samples were stained with a monoclonal mouse anti-FOXM1 antibody (clone 3A9; Abnova, Taipei, Taiwan), monoclonal mouse anti-BRAFV600E antibody (clone VE1; Spring Bioscience, Pleasanton, CA) and monoclonal rabbit anti-phospho-AKT (Ser473) antibody (Cell Signaling Technologies, Tokyo, Japan).

Techniques: Transfection, Control, Quantitative RT-PCR, Western Blot, BrdU Cell Proliferation Assay, MANN-WHITNEY

The expression of FOXM1 was assessed using a Western blotting analysis. The human melanoma cell lines were treated with 10 μM of MEK1 siRNA for 72 hours.

Journal: PLoS ONE

Article Title: Investigation of FOXM1 as a Potential New Target for Melanoma

doi: 10.1371/journal.pone.0144241

Figure Lengend Snippet: The expression of FOXM1 was assessed using a Western blotting analysis. The human melanoma cell lines were treated with 10 μM of MEK1 siRNA for 72 hours.

Article Snippet: Sections of paraffin-embedded melanomas and nevus tissue samples were stained with a monoclonal mouse anti-FOXM1 antibody (clone 3A9; Abnova, Taipei, Taiwan), monoclonal mouse anti-BRAFV600E antibody (clone VE1; Spring Bioscience, Pleasanton, CA) and monoclonal rabbit anti-phospho-AKT (Ser473) antibody (Cell Signaling Technologies, Tokyo, Japan).

Techniques: Expressing, Western Blot

(a) The expression of activated AKT was assessed by a Western blotting analysis using phospho-specific anti-AKT antibodies. (b) The results of the Western blotting analysis of the cell lysates from the human melanoma cell lines treated with LY294002 (30 μM) and an AKT inhibitor (20 μM) for 24 hours. The levels of FOXM1, p-AKT (ser 473) and AKT were determined. (c) Melanoma cell lines were transfected with control or FOXM1 siRNA, and a Western blotting was carried out with p-AKT (ser 473), AKT and FOXM1 antibodies 72 hours after treatment.

Journal: PLoS ONE

Article Title: Investigation of FOXM1 as a Potential New Target for Melanoma

doi: 10.1371/journal.pone.0144241

Figure Lengend Snippet: (a) The expression of activated AKT was assessed by a Western blotting analysis using phospho-specific anti-AKT antibodies. (b) The results of the Western blotting analysis of the cell lysates from the human melanoma cell lines treated with LY294002 (30 μM) and an AKT inhibitor (20 μM) for 24 hours. The levels of FOXM1, p-AKT (ser 473) and AKT were determined. (c) Melanoma cell lines were transfected with control or FOXM1 siRNA, and a Western blotting was carried out with p-AKT (ser 473), AKT and FOXM1 antibodies 72 hours after treatment.

Article Snippet: Sections of paraffin-embedded melanomas and nevus tissue samples were stained with a monoclonal mouse anti-FOXM1 antibody (clone 3A9; Abnova, Taipei, Taiwan), monoclonal mouse anti-BRAFV600E antibody (clone VE1; Spring Bioscience, Pleasanton, CA) and monoclonal rabbit anti-phospho-AKT (Ser473) antibody (Cell Signaling Technologies, Tokyo, Japan).

Techniques: Expressing, Western Blot, Transfection, Control

Journal: eLife

Article Title: BRAF V600E induces reversible mitotic arrest in human melanocytes via microrna-mediated suppression of AURKB

doi: 10.7554/eLife.70385

Figure Lengend Snippet:

Article Snippet: Membranes were incubated overnight at 4°C with primary antibodies at the following dilutions: anti-HSP90 (CST, 4874) 1:1000, anti-BRAFV600E (Spring Bioscience Corp, E19292) 1:1000, anti-phosphoERK1/2 (CST, 4970) 1:1000, and anti-AURKB (Abcam, ab2254) 1:1000.

Techniques: Derivative Assay, Western Blot, Recombinant, Sequencing, Control